A Monte Carlo simulation approach to the characterization of uncertainties in cancer staging and radiation treatment decisions

Radiation treatment (RT) for cancer is a critical medical procedure that occurs in a complex environment that is subject to uncertainties and errors. We employed a simulation (a variant of Monte Carlo) model that followed a cohort of hypothetical breast cancer patients to estimate the probability of incorrect staging and treatment decisions. As inputs, we used a combination of literature information and expert judgement. Input variables were defined as probability distributions within the model. Uncertainties were propagated via simulation. Sensitivity and value-of-information analyses were then conducted to quantify the effect of variable uncertainty on the model outputs. We found a small but non-trivial probability that patients would be incorrectly staged and thus be subjected to inappropriate treatment. Some routinely used tests for staging and metastasis detection have very limited informational value. This work has implications for the methods used in cancer staging and subsequent risk assessment of treatment errors.

[1]  G J Rosenbusch,et al.  [Reliability of sonography in diagnosing liver metastases in breast and bronchial cancer. A retrospective comparison of physical examination, laboratory tests and liver scintigraphy]. , 1986, Ultraschall in der Medizin.

[2]  Max Henrion,et al.  Uncertainty: A Guide to Dealing with Uncertainty in Quantitative Risk and Policy Analysis , 1990 .

[3]  B J McNeil,et al.  Computed tomography, ultrasound, and scintigraphy of the liver in patients with colon or breast carcinoma: a prospective comparison. , 1983, Radiology.

[4]  A. Lluch,et al.  Value of CA 15.3 in breast cancer and comparison with CEA and TPA: A study of specificity in disease-free follow-up patients and sensitivity in patients at diagnosis of the first metastasis , 2005, Breast Cancer Research and Treatment.

[5]  A. Vecchione,et al.  Comparison of CEA, MCA, CA 15-3 and CA 27-29 in follow-up and monitoring therapeutic response in breast cancer patients. , 1999, Anticancer research.

[6]  Gisela del Rocío Estrada Sánchez,et al.  Confiabilidad del CA 15-3 como seguimiento en las pacientes con carcinoma mamario y metástasis óseas , 2003 .

[7]  L. Frati,et al.  Skeletal alkaline phosphatase as a serum marker of bone metastases in the follow-up of patients with breast cancer , 1995, The International journal of biological markers.

[8]  S. Yasuda,et al.  Whole body PET for the evaluation of bony metastases in patients with breast cancer: comparison with 99Tcm-MDP bone scintigraphy , 2001, Nuclear medicine communications.

[9]  Dino Amadori,et al.  Staging of Breast Cancer: New Recommended Standard Procedure , 2002, Breast Cancer Research and Treatment.

[10]  J O Prior,et al.  The value of bone marrow scintigraphy using 99mTc monoclonal antigranulocyte antibodies in complement to bone scintigraphy in detecting bone metastases from primary breast cancer , 2003, Nuclear medicine communications.

[11]  E. Imhoff,et al.  Comparison of whole-body MRI with automatic moving table technique and bone scintigraphy for screening for bone metastases in patients with breast cancer , 2004, European Radiology.

[12]  J Hermans,et al.  Prospective comparative study of ultrasound, CT-scan, scintigraphy and laboratory tests to detect hepatic metastases. , 1991, Journal of nuclear biology and medicine.

[13]  A. Fasoli [Clinical decision analysis]. , 1986, Annali italiani di medicina interna : organo ufficiale della Societa italiana di medicina interna.

[14]  B Padovani,et al.  Etiologic diagnosis of hepatic lesions in cancer patients. Value of ultrasound and liver function tests. , 1997, Clinical imaging.

[15]  Peter Norvig,et al.  Artificial Intelligence: A Modern Approach , 1995 .

[16]  J Hermans,et al.  Hepatic metastases: comparative study of diagnostic ultrasound, CT, nuclear scintigraphy and laboratory tests. , 1991, The Netherlands journal of surgery.

[17]  J. Dowie,et al.  ‘Evidence-based’, ‘Cost-Effective’ and ‘Preference-Driven’ Medicine: Decision Analysis Based Medical Decision Making is the Pre-Requisite , 1996, Journal of health services research & policy.

[18]  T. Mcgarrity,et al.  An analysis of imaging studies and liver function tests to detect hepatic neoplasia , 1987, Digestive Diseases and Sciences.

[19]  A Spanu,et al.  The role of (99m)Tc-tetrofosmin pinhole-SPECT in breast cancer non palpable axillary lymph node metastases detection. , 2003, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

[20]  A Pupi,et al.  Staging Breast Cancer - Screening for Occult Metastases , 1985, Tumori.

[21]  M. Góralczyk,et al.  [Elevation of serum Ca 15-3 antigen: an early indicator of distant metastasis from breast cancer. Retrospective analysis of 733 cases]. , 2001, Przeglad lekarski.

[22]  W. Yasmineh,et al.  Value of alkaline phosphatase, 5'-nucleotidase, gamma-glutamyltransferase, and glutamate dehydrogenase activity measurements (single and combined) in serum in diagnosis of metastasis to the liver. , 1977, Clinical chemistry.

[23]  F. J. Davis,et al.  Illustration of Sampling‐Based Methods for Uncertainty and Sensitivity Analysis , 2002, Risk analysis : an official publication of the Society for Risk Analysis.

[24]  F. Guadagni,et al.  A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: a prospective longitudinal study. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[25]  Gisela del Rocío Estrada-Sánchez,et al.  [Reliability of CA 15-3 in the follow up of female patients with breast carcinoma and bone metastases]. , 2003, Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion.

[26]  A. Y. Foo,et al.  Measurement of biliary alkaline phosphatase by mini-column chromatography and by electrophoresis and its application to the detection of liver metastases in patients with breast cancer. , 1984, Journal of clinical pathology.

[27]  Hans-Jürgen Gallowitsch,et al.  F-18 Fluorodeoxyglucose Positron-Emission Tomography in the Diagnosis of Tumor Recurrence and Metastases in the Follow-Up of Patients With Breast Carcinoma: A Comparison to Conventional Imaging , 2003, Investigative radiology.

[28]  M Torres,et al.  CA 549 and SP2 in postoperative breast cancer patients. Comparison with CA 15.3, CEA and TPA , 1995, The International journal of biological markers.

[29]  K. Holli,et al.  Role of Chest X-ray in Diagnosis of the First Breast Cancer Relapse: A Randomized Trial , 2003, Breast Cancer Research and Treatment.

[30]  M. Hou,et al.  Evaluation of serum CA27.29, CA15-3 and CEA in patients with breast cancer. , 1999, The Kaohsiung journal of medical sciences.

[31]  Z Kusić,et al.  Bone marrow immunoscintigraphy for the detection of skeletal metastases in patients with breast cancer. , 1999, Nuclear medicine communications.

[32]  C A Williams,et al.  The value of hepatic ultrasound and biochemical liver tests in screening for liver metastases. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  Monica Morrow,et al.  Changes in breast cancer therapy because of pathology second opinions , 2002, Annals of Surgical Oncology.

[34]  R C Lee,et al.  221 DEVELOPMENT OF HUMAN EXPOSURE-FACTOR DISTRIBUTIONS USING MAXIMUM-ENTROPY INFERENCE , 1995 .

[35]  Fiorella Guadagni,et al.  Serum tissue polypeptide specific antigen (TPS): a complementary tumor marker to CA 15-3 in the management of breast cancer , 2001, Breast Cancer Research and Treatment.

[36]  W. H. M. Schattevoet,et al.  Die Zuverlässigkeit der Sonographie bei der Diagnostik von Lebermetastasen beim Mamma- und Bronchialkarzinom , 2008 .

[37]  W. D. Bostick,et al.  Biological markers as an aid in the clinical management of patients with liver metastases , 1982, Journal of surgical oncology.

[38]  R. Sirota,et al.  Derivation of a new hematopoietic cell line with endothelial features from a patient with transformed myeloproliferative syndrome , 2000, Cancer.

[39]  G Parmigiani,et al.  Measuring uncertainty in complex decision analysis models , 2002, Statistical methods in medical research.

[40]  C. Eggers,et al.  CANCER OF THE BREAST , 1941, Annals of surgery.

[41]  David C. Smith,et al.  Randomised controlled trial of conservation therapy for breast cancer: 6-year analysis of the Scottish trial , 1996, The Lancet.

[42]  B. E. F. Isher,et al.  Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. , 2002 .

[43]  Norman Wolmark,et al.  Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  M Untch,et al.  Alkaline phosphatase isoenzymes in detection and follow up of breast cancer metastases. , 1998, Anticancer research.